Results 201 to 208 of about 13,569 (208)

Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY).

International Journal of Cardiology, 2013
M. Valgimigli, G. Campo, Stefania Gambetti, L. Bolognese, F. Ribichini, S. Colangelo, N. D. De Cesare, Alfredo E. Rodríguez, F. Russo, R. Moreno, T. Piva, I. Sheiban, C. Penzo, F. Prati, M. Nazzaro, J. D. Díaz Fernández, C. Vassanelli, G. Parrinello, R. Ferrari   +18 more
semanticscholar   +1 more source

Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study

Lancet, The, 1997
exaly  

Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Circulation, 2008
Holger Thiele, Ingo Eitel
exaly  

Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: a meta-analysis of clinical trials.

International Journal of Cardiology, 2013
S. de Rosa, G. Caiazzo, D. Torella, C. Indolfi   +3 more
semanticscholar   +1 more source

Abciximab-Supported Infarct Artery Stent Implantation for Acute Myocardial Infarction and Long-Term Survival

Circulation, 2004
David Antoniucci, Guido Parodi
exaly  

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

Lancet, The, 2001
exaly  

Mortality in intracoronary versus intravenous abciximab

Lancet, The, 2012
exaly   +2 more sources

Coronary stenting and use of abciximab

Lancet, The, 1998
exaly